Answers are grounded in this paper and cite their sources.
This study contributes to understanding the clinical and genetic landscape of breast and ovarian cancer susceptibility. Extending clinical genetic screening from BRCA1 and BRCA2 to 13 established cancer predisposition genes almost doubles the diagnostic yield, which has implications for genetic counseling and clinical guidelines. The very low yield in the syndrome genes CDH1, PTEN and STK11 questions the usefulness of including these genes on routine gene panels.
No takes yet. Share an insight, caveat, or question.
Öfverholm et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: